Aviptadil
Aliases: VIP · Vasoactive Intestinal Peptide · RLF-100 · Zyesami
Last verified: 2026-09-23
The short version
Synthetic VIP (28 aa) — vasodilatory and anti-inflammatory neuropeptide; investigated for ARDS/COVID-19, pulmonary hypertension and erectile dysfunction. Status: in clinical trials. Partially approved (UK, ED combination); otherwise investigational.
Identity & type
- Molecular type
- analog
- Origin
- Synthetic VIP (28 aa) — vasodilatory and anti-inflammatory neuropeptide; investigated for ARDS/COVID-19, pulmonary hypertension and erectile dysfunction.
Mechanism of action
VPAC1/VPAC2 receptors → cAMP → vasodilation, immunomodulation, alveolar protection.
Dosing & routes
Official / clinical context
No approved official document exists for Aviptadil. Any protocols mentioned are to be read as information, not as a recommendation.
Regulator-approved labeling and published study designs — never a recommendation.
Community-reported practice
Trials IV/inhaled; erectile intracavernosal (with phentolamine). Investigational: improved oxygenation reported in ARDS/COVID studies; the community barely uses it (unavailable).
Unverified self-reports. Not medical advice. Not endorsement.
Expected effects (community)
Investigational: improved oxygenation reported in ARDS/COVID studies; the community barely uses it (unavailable).
Protocol — official vs community
Official / label
No approved protocol exists as a standalone drug — investigational agent. Approved in the UK only as one component of Invicorp (intracavernosal aviptadil 25 mcg + phentolamine for erectile dysfunction). Clinical research programs used IV and inhaled dosing for ARDS.
Duration: Indication- and study-dependent; no chronic standalone protocol exists.
The COVID-19 ARDS trials produced mixed results and no approval. Hypotension, flushing and tachycardia are the dose-limiting effects of its VPAC agonism.
Community (anecdotal)
Community use is minimal and mostly experimental-injection-scene; where it appears it loosely tracks the trial tradition (IV/inhaled in clinical settings, intracavernosal only within the approved combination).
- Cycle:
- No standardized pattern.
- Break:
- —
There is no meaningful gray-market aviptadil culture — its hypotensive profile makes unsupervised use unattractive. 'Approved in the UK' applies only to the Invicorp combination, not to injectable VIP as a research chemical.
Human evidence
Phase II/III COVID-19 ARDS (mixed results); approved in UK within Invicorp (ED).
Preclinical evidence
Preclinical literature preceded the clinical trials; details vary by compound.
Known risks
- Hypotension, flushing, tachycardia.characterized
- Unregulated injectable supply — sterility, purity and accurate dose not assuredtheoretical
Teal: characterized in clinical/labeling contexts. Amber: theoretical or reported outside controlled settings.
Unknowns & evidence gaps
- Long-term safety in off-label use
Frequently asked questions
References
Systematic references are being expanded; verify sources directly before any decision.